Company / Cost of Revenue
BIOMERICA INC Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$4.8M
FY2024
5-year range
$4.8M / $15.9M
FY2020-FY2024
Trend
+0.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue returned to growth in FY2024 after 2 years of decline, reaching $5M.
Based on SEC 10-K filings.
$5M in FY2024 with a 5-year CAGR of +4.3%.
Remained stable around $5M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -32.8%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2024, cost of revenue increased 0.2% year-over-year.
- Peak cost of revenue was recorded in FY2021.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $4.8M | +0.2% |
| FY2023 | $4.8M | -1.8% |
| FY2022 | $4.9M | -69.2% |
| FY2021 | $15.9M | +132.6% |
| FY2020 | $6.8M | +74.8% |
| FY2019 | $3.9M | +0.0% |
| FY2018 | $3.9M | +2.6% |
| FY2017 | $3.8M | +1.1% |
| FY2016 | $3.8M | +4.3% |
As of FY2024 · SEC Form 10-K · Last checked Jun 22, 2026